Loading clinical trials...

Comparing Water Vapour Thermal Therapy (Rezūm) and TURP | Clinical Trials | Clareo Health

RECRUITINGNA

Comparing Water Vapour Thermal Therapy (Rezūm) and TURP

A Randomized Controlled Trial Comparing Water Vapour Thermal Therapy (Rezūm) and TURP in Men With Benign Prostatic Hyperplasia in Refractory Urinary Retention

NCT05762198•Chinese University of Hong Kong

View on ClinicalTrials.gov

Summary

This is a randomized controlled trial using a non-inferiority design with the subjects randomized 1:1 to either water vapour thermal treatment (REZUM) arm or transurethral resection of prostate (TURP) arm.

Eligibility

Age

50 - 80 years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Men 50-80 years
•Refractory urinary retention related to benign prostatic hyperplasia (BPH)
•On urethral Foley's catheter before treatment
•Prostate size 30-80ml on ultrasound

Exclusion Criteria

•Prior prostate operation
•Past or current history of prostate cancer
•Strong suspicion of prostate cancer (e.g. Elevated PSA before urinary retention or abnormal prostate on DRE without workup for prostate cancer)
•Known Urethral stricture / Bladder stone / Hypocontractile bladder
•Known neurological diseases which may affect bladder function (e.g. Parkinsonism, stroke)
•Contraindicated to undergo TURP or REZUM (e.g. not fit for GA/SA, active urinary tract infection, fail to be placed in lithotomy position, uncorrectable coagulopathy, antiplatelet or anticoagulant which cannot be stopped)

Locations (1)

Prince of Wales Hospital, Chinese University of Hong Kong

Hong Kong, Hong Kong

Key Dates

Start Date

May 1, 2023

Primary Completion Date

April 30, 2026

Completion Date

June 30, 2026

Last Updated

May 7, 2025

Enrollment

108

ESTIMATED participants

Conditions

Prostate Cancer

Interventions

Rezūm

DEVICE

TURP

DEVICE

Contacts

Peter Ka-Fung CHIU, FRCS, PhD

CONTACT

35051663 peterchiu@surgery.cuhk.edu.hk

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

RECRUITINGPHASE2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465

Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate Neuroendocrine Carcinoma+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 7, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Comparing Water Vapour Thermal Therapy (Rezūm) and TURP

Inclusion Criteria

Exclusion Criteria

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC